Baertsch, M., Schlenzka, J., Mai, E., Merz, M., Hillengaß, J., Raab, M., Hose, D., Wuchter, P., Ho, A., Jauch, A., Hielscher, T., Kunz, C., Luntz, S., Klein, S., Schmidt-Wolf, I., Goerner, M., Schmidt-Hieber, M., Reimer, P., Graeven, U., Fenk, R., Salwender, H., Scheid, C., Nogai, A., Haenel, M., Lindemann, H., Martin, H., Noppeney, R., Weisel, K., & Goldschmidt, H. (2016). rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC cancer, 16(1), 1–10. http://access.bl.uk/ark:/81055/vdc_100080452790.0x000165